Bo Kara - Mereo BioPharma Senior CMC

0A9G Stock   2.61  0.08  3.16%   

Executive

Bo Kara is Senior CMC of Mereo BioPharma Group
Phone44 33 3023 7300
Webhttps://www.mereobiopharma.com

Mereo BioPharma Management Efficiency

The company has return on total asset (ROA) of (0.3065) % which means that it has lost $0.3065 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6211) %, meaning that it generated substantial loss on money invested by shareholders. Mereo BioPharma's management efficiency ratios could be used to measure how well Mereo BioPharma manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Showing other executives

EXECUTIVE Age

Jacqueline WoodsTeradata Corp
62
Alexandra BrooksFidelity National Information
54
Matt GarvieTeradata Corp
N/A
Lainie CPATake Two Interactive Software
57
James BushellGamma Communications PLC
N/A
Guy HainsFidelity National Information
73
Louis LandryTeradata Corp
N/A
Christopher ThompsonFidelity National Information
60
Sarah EnglandGamma Communications PLC
N/A
Claire BramleyTeradata Corp
47
Steve HoldenGamma Communications PLC
N/A
Christophe KasolowskyAptitude Software Group
N/A
Lainie GoldsteinTake Two Interactive Software
56
Hillary AshtonTeradata Corp
53
Phil StubbsGamma Communications PLC
N/A
David IsmailerTake Two Interactive Software
N/A
Robert TooheyFidelity National Information
57
Kathleen CullenCoteTeradata Corp
59
Darren PoyntonSilver Bullet Data
52
Daniel EmersonTake Two Interactive Software
52
Michael HutchinsonTeradata Corp
59
Mereo BioPharma Group (0A9G) is traded on London Exchange in UK and employs 33 people.

Management Performance

Mereo BioPharma Group Leadership Team

Elected by the shareholders, the Mereo BioPharma's board of directors comprises two types of representatives: Mereo BioPharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mereo. The board's role is to monitor Mereo BioPharma's management team and ensure that shareholders' interests are well served. Mereo BioPharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mereo BioPharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Christine CPA, Chief Officer
Bo Kara, Senior CMC
Fiona Bor, Head Property
Charles Sermon, General CoFounder
MBBS MD, CoFounder Strategy
John Lewicki, Chief Officer
Jackie Parkin, Therapy Endocrinology
Alexandra HughesWilson, Chief Planning
John MBA, CoFounder Officer
Denise ScotsKnight, CEO CoFounder
Suba Krishnan, Senior Development
MBA MBA, CoFounder Officer

Mereo Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mereo BioPharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Mereo Stock Analysis

When running Mereo BioPharma's price analysis, check to measure Mereo BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo BioPharma is operating at the current time. Most of Mereo BioPharma's value examination focuses on studying past and present price action to predict the probability of Mereo BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mereo BioPharma's price. Additionally, you may evaluate how the addition of Mereo BioPharma to your portfolios can decrease your overall portfolio volatility.